Exciting Times for Lipid Nanoparticles: How Canadian Discoveries Are Enabling Gene Therapies

Miffy H Y Cheng; Cedric A Brimacombe; Rein Verbeke; Pieter R Cullis

doi:10.1021/acs.molpharmaceut.2c00365

Exciting Times for Lipid Nanoparticles: How Canadian Discoveries Are Enabling Gene Therapies

Mol Pharm. 2022 Jun 6;19(6):1663-1668. doi: 10.1021/acs.molpharmaceut.2c00365. Epub 2022 May 18.

Authors

Miffy H Y Cheng¹, Cedric A Brimacombe², Rein Verbeke^{1

3}, Pieter R Cullis¹

Affiliations

¹ Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada.
² Polymorphic BioSciences, Vancouver, British Columbia V6T 1Z3, Canada.
³ Ghent Research Group on Nanomedicines, Faculty of Pharmacy, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium.

PMID: 35583489
DOI: 10.1021/acs.molpharmaceut.2c00365

Abstract

In this brief perspective, we describe key events in the history of the lipid-based nanomedicine field, highlight Canadian contributions, and outline areas where lipid nanoparticle technology is poised to have a transformative effect on the future of medicine.

Keywords: CAR-T therapy; CRISPR-Cas9; gene therapy; lipid nanoparticles; mRNA; vaccines.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

CRISPR-Cas Systems
Canada
Gene Editing*
Liposomes
Nanoparticles*

Substances

Lipid Nanoparticles
Liposomes

Grants and funding

FDN 148469/CIHR/Canada